MEI Pharma Inc - ESG Rating & Company Profile powered by AI
This webpage of MEI Pharma Inc was assembled by All Street Sevva using advanced machine learning. If you are employed by MEI Pharma Inc and you wish to use your Sustainability rating, please contact us. The ESG rating covers 17 United Nations Sustainable Development Goals including: 'Gender Equality', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'.
MEI Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 2.7, social score of 6.4 and governance score of 8.0.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 541 | Wntresearch AB | 5.8 | High |
| 541 | Zenotech Laboratories Ltd | 5.8 | High |
| 579 | MEI Pharma Inc | 5.7 | High |
| 579 | Caplin Point Laboratories Ltd | 5.7 | High |
| 579 | Biotest AG | 5.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does MEI Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes MEI Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes MEI Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes MEI Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes MEI Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes MEI Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes MEI Pharma Inc offer flexible work?
Sign up for free to unlockDoes MEI Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes MEI Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes MEI Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes MEI Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes MEI Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes MEI Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes MEI Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes MEI Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes MEI Pharma Inc disclose water use targets?
Sign up for free to unlockDoes MEI Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid MEI Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes MEI Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes MEI Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas MEI Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes MEI Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes MEI Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes MEI Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes MEI Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes MEI Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes MEI Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes MEI Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs MEI Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes MEI Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes MEI Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes MEI Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes MEI Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes MEI Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes MEI Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes MEI Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for MEI Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.